United States Food and Drug Administration (USFDA) has approved United States-based Merck's anti-PD-1 therapy Keytruda (pembrolizumab) intended for treatment of head and neck cancer, it was reported yesterday.
The regulator has approved the product as monotherapy and in combination with chemotherapy regimen platinum and fluorouracil. The approval is for first-line treatment of metastatic or with unresectable, recurrent head and neck squamous cell carcinoma as monotherapy in patients whose tumours express the biomarker PD-L1.
The drug's approval in combination with fluorouracil is for the treatment of the same condition, irrespective of PD-L1 expression.
The product received extended approval as a result of the findings of a phase three KEYNOTE-048 trial in which the product significantly improved overall survival in comparison to the EXTREME regimen (cetuximab with carboplatin or cisplatin plus fluorouracil). This was showcased with the drug used as monotherapy and in combination with chemotherapy.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886